Artelo Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARTL Nasdaq 2830 www.artelobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artelo Biosciences, Inc.

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - Mar 3rd, 2025 1:00 pm
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - Feb 14th, 2025 2:00 pm
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland - Feb 11th, 2025 2:00 pm
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - Jan 13th, 2025 2:00 pm
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia - Dec 10th, 2024 2:43 pm
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia - Dec 9th, 2024 2:15 pm
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit - Nov 18th, 2024 1:30 pm
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium - Nov 13th, 2024 1:30 pm
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 12th, 2024 1:00 pm
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program - Nov 5th, 2024 1:30 pm
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th - Oct 9th, 2024 1:00 pm
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 1:00 pm
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Aug 13th, 2024 12:00 pm
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor - Jul 15th, 2024 12:30 pm
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium - Jul 3rd, 2024 1:00 pm
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform - Jul 2nd, 2024 1:00 pm
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium - Jul 1st, 2024 1:00 pm
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society - Jun 4th, 2024 12:30 pm
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24 - May 29th, 2024 12:30 pm
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update - May 13th, 2024 12:00 pm